Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1041024 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $6.88Day −1.57%Mkt cap $272M1Y −32.5%Off 52W high −87.9%Vol (1Y) 79.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 4,013 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.2% of sh out |
| Days to cover2.0d |
| 13F net flow (QoQ)+0.65% |
| Top-10 13F concentration84.2% |
| Next report (est.)2026-08-07 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$67.7M |
| Earnings (TTM)-$5.4M |
| ROE−15.3% |
| Net margin−7.7% |
| ROIC−12.3% |
| Debt / equity0.24× |
| Sales growth 3Y−1.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−17.1% |
| 1Y−32.5% |
| 3Y−80.7% |
| 5Y−91.6% |
| 10Y−99.2% |
| Since incept. (ann.)−25.1% |
Total return through 2026-07-29 · series begins 2010-01-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)79.2% |
| Ann. volatility (3Y)78.5% |
| Sharpe (1Y)−0.14 |
| Sharpe (3Y)−0.31 |
| Max drawdown (1Y)−70.7% |
| Max drawdown (3Y)−88.5% |
| Beta (3Y vs SPY)1.10 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $1M | 3.00% | new |
| RENAISSANCE TECHNOLOGIES LLC | 639,120 | $570,862 | 1.62% | +36.5% |
| GEODE CAPITAL MANAGEMENT, LLC | 429,180 | $383,415 | 1.09% | +17.6% |
| BlackRock, Inc. | 236,671 | $211,395 | 0.60% | +7.2% |
| VANGUARD FIDUCIARY TRUST CO | 231,258 | $206,513 | 0.59% | new |
| UBS Group AG | 178,886 | $159,745 | 0.45% | +28.0% |
| Wealthspire Advisors, LLC | 151,838 | $135,622 | 0.38% | new |
| NORTHERN TRUST CORP | 104,523 | $93,360 | 0.26% | +2.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | — | — | $17.3M | −8.3% |
| 2025-12-31 | 2026-03-26 | — | — | $18.3M | −25.6% |
| 2025-09-30 | 2025-11-12 | — | — | $15.9M | −43.8% |
| 2025-06-30 | 2025-08-14 | — | — | $16.1M | −37.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
